Safety and Tolerability of Idelalisib, Lenalidomide, and Rituximab in Relapsed and Refractory Lymphoma: Alliance A051201 and A051202 Phase I Trials

BACKGROUND: A new generation of biologic and targeted agents may potentially replace traditional cytotoxic agents in lymphoma. Lenalidomide plus rituximab was felt to be a safe and promising backbone based on available data. Idelalisib is an oral PI3Kδ inhibitor approved for relapsed/refractory indo...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Lancet Haematol
Autori principali: Smith, Sonali M., Pitcher, Brandelyn N., Jung, Sin-Ho, Bartlett, Nancy L., Wagner-Johnston, Nina, Park, Steven I., Richards, Kristy L., Cashen, Amanda F., Jaslowski, Anthony, Smith, Scott E., Cheson, Bruce D., Hsi, Eric, Leonard, John P.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5499150/
https://ncbi.nlm.nih.gov/pubmed/28314699
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(17)30028-5
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi